Insulin Regular

Introduction Overview

Generic Name

Insulin Regular

Brand Name

HumuLIN R, Myxredlin, NovoLIN R

Dosage Form

Injection solution (vial, cartridge, prefilled pen), intravenous infusion

Drug Class

Insulin

Pharmacokinetics

Absorption:
Regular insulin is typically administered subcutaneously and is classified as a short-acting insulin. Upon subcutaneous injection, insulin regular exhibits onset of action within 30 minutes to 1 hour. The peak plasma concentration is generally reached between 2 to 5 hours post-injection, and the duration of effect lasts approximately 6 hours. The absorption rate is influenced by the injection site; abdominal injections typically lead to faster absorption compared to the thigh or buttocks due to regional blood flow differences. Factors such as skin temperature, physical activity, and depth of injection can modulate absorption kinetics. Intravenous administration results in immediate availability with no absorption delay.

Distribution:
Once absorbed, insulin distributes primarily in the extracellular fluid compartment. The volume of distribution for insulin regular is approximately 0.2 to 0.3 L/kg. Insulin binds with negligible affinity to plasma proteins, except for transient binding to insulin receptors and soluble insulin-binding proteins. Its distribution is rapid, facilitated by its molecular size and hydrophilic nature, allowing quick diffusion into target tissues such as muscle and adipose tissue. Insulin receptor expression in these tissues modulates its pharmacodynamic effects.

Metabolism:
Insulin regular undergoes extensive first-pass metabolism predominantly in the liver (approximately 60% of circulating insulin is cleared hepatically) and kidneys (25-35%). In these organs, insulin is enzymatically degraded primarily by insulin-degrading enzyme (IDE) and other proteases. The pancreas and peripheral tissues contribute to a minor extent to insulin metabolism. Alterations in hepatic or renal function can significantly impact insulin clearance and thus influence dosing requirements.

Elimination:
The elimination half-life of insulin regular after subcutaneous administration averages between 4 to 6 hours, corresponding with its duration of glucose-lowering action. Insulin is primarily eliminated via receptor-mediated endocytosis and lysosomal degradation within liver and kidney tissues. Renal impairment can lead to prolonged insulin action due to reduced clearance. Insulin is not eliminated renally unchanged but rather metabolized; thus, accumulation of insulin itself is uncommon unless metabolic processes are impaired. Understanding the elimination profile is crucial for dose adjustment in patients with organ dysfunction.

Dosage Forms

Available Dosage Forms:
Regular insulin is available in the form of sterile aqueous solutions intended for injection. Common dosage forms include:
- U-100 concentration (100 units/mL) in vials, cartridges for pen injectors, and prefilled pens
- U-500 concentration (500 units/mL) in vials and KwikPen prefilled pens for highly insulin-resistant patients
- Intravenous formulations used in hospital settings for acute glycemic control

Dosages for Adults and Adolescents:
Dosing of regular insulin is individualized based on patient requirements, blood glucose monitoring, and glycemic control targets. For adults and adolescents, initial dosing usually involves a basal-bolus regimen where regular insulin is administered 30 minutes before meals to control postprandial glucose spikes. Typical meal-time doses may start at 0.1 to 0.2 units/kg and are titrated based on glucose measurements. In insulin regimens, regular insulin is often combined with intermediate or long-acting insulin analogs for basal glycemic control.

Specific Patient Populations:
- Pediatric Use: Insulin regular is not approved for use in children under 2 years of age, and generally children with type 1 diabetes over 2 years may require individualized dosing.
- Renal or Hepatic Impairment: Due to altered metabolism and clearance, dose adjustments and careful monitoring of blood glucose are essential.
- Pregnancy: Insulin regular is considered safe and frequently used in gestational diabetes and pregnant women with diabetes, with dosing tailored to maintain strict glycemic control.

Clinical guidelines emphasize that insulin regimens must be personalized and always administered subcutaneously except in hospital settings where intravenous use is appropriate for emergencies like diabetic ketoacidosis.

Mechanism Of Action

Insulin regular functions by mimicking endogenous human insulin, a peptide hormone critical for carbohydrate, fat, and protein metabolism. Molecularly, it binds to insulin receptors located on the cell membranes of target tissues, primarily muscle and adipose tissue. The binding initiates autophosphorylation of the receptor's intrinsic tyrosine kinase domains, triggering a cascade of intracellular signaling pathways including insulin receptor substrates (IRS), phosphatidylinositol 3-kinase (PI3K), and Akt/protein kinase B.

Activation of these pathways promotes translocation of glucose transporter type 4 (GLUT4) vesicles to the cell surface, enhancing glucose uptake into cells. This results in a reduction of plasma glucose concentrations. Additionally, insulin modulates several anabolic processes: it stimulates glycogenesis (glycogen formation), lipogenesis (fat storage), and protein synthesis while inhibiting gluconeogenesis, glycogenolysis, and lipolysis. These combined effects maintain glucose homeostasis and energy balance.

Clinically, regular insulin's pharmacological activity includes controlling postprandial blood glucose by its short onset and peak action time. Unlike rapid-acting insulin analogs, regular insulin requires administration approximately 30 minutes before meals to align with glucose absorption. Its mechanism closely represents endogenous insulin but with a predictable pharmacokinetic profile leveraged for diabetes management.

Comparative studies show that while rapid-acting analogs provide more physiological postprandial glucose control, regular insulin remains an effective and economical option, particularly in resource-limited settings. Research continuously elucidates its receptor interactions and downstream signaling, fostering development of improved insulin analogs.

Pharmacological Actions

Lowers blood glucose by facilitating cellular uptake particularly in muscle and adipose tissue.
Inhibits hepatic glucose production through suppression of gluconeogenesis and glycogenolysis.
Promotes glycogen synthesis in liver and muscle cells.
Stimulates lipogenesis and inhibits lipolysis, promoting fat storage.
Enhances protein synthesis and inhibits proteolysis.
Reduces blood ketone levels by inhibiting ketogenesis.
Regulates electrolyte balance by increasing cellular uptake of potassium and phosphate.
Exerts anabolic effects thus aiding in tissue repair and growth.
Compensates for endogenous insulin deficiency in type 1 diabetes mellitus.
Adjunctive in type 2 diabetes when oral agents and other insulins are insufficient.
Used intravenously in acute hyperglycemic emergencies such as diabetic ketoacidosis and hyperosmolar hyperglycemic state.
Short-acting profile allows for precise timing before meals to control postprandial glucose excursions.
Useful in gestational diabetes to maintain maternal and fetal euglycemia.
Can prevent long-term microvascular and macrovascular complications by maintaining glycemic control.
Dose and effect can be titrated, allowing personalized treatment regimens.

Therapeutic Or Clinical Uses

Management of type 1 diabetes mellitus to replace deficient endogenous insulin.
Treatment of type 2 diabetes mellitus when oral hypoglycemic agents fail to achieve glycemic control.
Control of gestational diabetes mellitus to prevent maternal and fetal complications.
Acute management of diabetic ketoacidosis and hyperosmolar hyperglycemic states via intravenous infusion.
Adjunctive therapy in combination with intermediate and long-acting insulins in basal-bolus regimens.
Used perioperatively and during critical illness for tight glycemic control in hospitalized patients.
Prevention of complications such as retinopathy, nephropathy, neuropathy through sustained euglycemia.
Treatment of severe insulin resistance with higher concentrations such as U-500 insulin formulations.
Temporary use in patients undergoing steroid therapy or other diabetogenic treatments.
Management of hyperglycemia in patients with pancreatic disorders or after pancreatic surgery.
Therapeutic choice in patients allergic or intolerant to insulin analogs.
Used in insulin pumps in specific circumstances, although regular insulin is generally not recommended for pump use due to pharmacokinetics.
Effective in managing blood sugar during pregnancy to optimize fetal outcomes.
Important in patients with fluctuating blood glucose levels requiring rapid titration.
Can be used in combination with GLP-1 receptor agonists or other antihyperglycemics under clinical guidance.

Side Or Adverse Effects

Hypoglycemia presenting with symptoms such as sweating, dizziness, headache, irritability, blurred vision, and in severe cases, seizures or loss of consciousness.
Local injection site reactions including pain, redness, swelling, and lipodystrophy manifesting as lipoatrophy or lipohypertrophy.
Weight gain due to anabolic effects promoting fat storage.
Allergic reactions ranging from local hypersensitivity to systemic anaphylaxis characterized by rash, urticaria, or respiratory distress.
Edema or fluid retention, occasionally observed with initiation of insulin therapy.
Hypokalemia due to insulin-stimulated intracellular potassium shift, potentially causing muscle cramps or cardiac arrhythmias.
Rare development of insulin resistance antibodies leading to impaired efficacy.
Injection site infections secondary to improper technique or contamination.
Rare systemic allergic responses such as angioedema or anaphylactoid reactions.
Visual changes or transient worsening of diabetic retinopathy with rapid glucose control.
Rare lipodystrophy associated with repeated injections at the same site without rotation.
Neuropathic symptoms may exacerbate temporarily during initiation of intensive insulin therapy.
Weight fluctuations especially if diet and exercise are not well regulated.
Hypersensitivity to preservatives in insulin formulations causing contact dermatitis.
Potential for medication errors leading to dosing inaccuracies, especially with high concentration formulations.

Precautions

Avoid use during episodes of hypoglycemia; insulin should not be administered when blood glucose is low.
Proper rotation of injection sites is essential to prevent lipodystrophy and ensure consistent absorption.
Patients with hepatic or renal impairment require close monitoring and possible dose adjustments.
Monitor potassium levels as insulin can cause hypokalemia; supplementation may be needed.
Educate patients on recognition and treatment of hypoglycemia including the use of glucose tablets or glucagon emergency kits.
Avoid abrupt changes in insulin brand or syringe types without medical consultation to prevent dosing errors.
Pregnant and breastfeeding women should use insulin regular under close clinical supervision.
Blood glucose monitoring should be frequent during dose titration and periods of stress, illness, or surgery.
Caution in elderly patients due to increased risk of hypoglycemia and comorbidities.
Contraindicated for intravenous use outside of medical supervision and dosing guidelines.
Patients should be instructed on proper storage; do not use insulin that is frozen, cloudy, or contains particles.
Avoid alcohol consumption which may potentiate hypoglycemia.
Be vigilant for allergic reactions; discontinue insulin if severe reactions occur and seek medical help.
Educate on safe disposal of needles and syringes to prevent infections and accidental injury.
Stress, certain medications, and changes in diet or exercise can affect insulin needs; maintain open communication with healthcare provider.

Warnings

Insulin regular must not be used to treat hypoglycemia; administration in low blood sugar states may worsen symptoms.
Severe hypoglycemia can be life-threatening and requires immediate treatment to prevent seizures, coma, and death.
Patients must carry readily accessible fast-acting carbohydrates (e.g., glucose tablets, fruit juice) at all times.
Injection into damaged, scarred, or inflamed skin should be avoided to prevent erratic absorption.
Insulin overdose is a medical emergency and presents with profound hypoglycemia; emergency medical attention is required.
Do not share insulin pens or syringes to prevent transmission of infections including HIV and hepatitis.
Switching insulin products or doses without medical advice can result in hyperglycemia or hypoglycemia.
Proper technique must be followed; insulin regular should not be given intravenously or intramuscularly outside hospital settings.
Patients using concomitant medications like pioglitazone or rosiglitazone should be monitored for risk of heart failure.
Increased blood glucose variability may result from altered insulin absorption due to lipodystrophy.
Do not use insulin that has changed color or become cloudy to prevent administration of inactive or unsafe product.
Exercise caution when driving or operating machinery due to risk of hypoglycemia-induced impairments.
Severe allergic reactions, including anaphylaxis, though rare, require immediate discontinuation and emergent care.
Patients should be counseled that stress, illness, or surgery may necessitate adjustment of insulin dose.
Emergency identification indicating diabetes and insulin use should be carried for rapid recognition in accidents.

Contraindication

Hypersensitivity or allergy to insulin or any component of the formulation.
Episodes of hypoglycemia or confirmed low blood glucose at time of intended insulin dose.
Inappropriate for treatment of type 2 diabetes in children of any age; not approved for pediatric use under 2 years.
Patients with severe hypokalemia should not receive insulin without potassium correction due to risk of arrhythmias.
Incompatible for intravenous use outside supervised acute settings (only certain preparations and concentrations are approved for IV use).
Acute diabetic emergencies where alternative insulin regimens or formulations are required.
Known allergy to preservatives or excipients contained in specific insulin preparations.
Patients unable to safely self-administer insulin or those without caregiver support in absence of appropriate supervision.
Use with caution or avoid in patients with uncorrected adrenal, pituitary or thyroid disorders which may affect glucose metabolism.
Patients with a history of recurrent severe hypoglycemia or hypoglycemia unawareness without appropriate monitoring capabilities.

Drug Interactions

Concurrent use of oral hypoglycemic agents such as sulfonylureas, meglitinides, or thiazolidinediones can potentiate hypoglycemic effects.
Pioglitazone and rosiglitazone combined with insulin may increase the risk of congestive heart failure.
Beta-blockers can mask symptoms of hypoglycemia, complicating recognition and treatment.
Alcohol consumption potentiates insulin hypoglycemic effects and may delay recovery from hypoglycemia.
Corticosteroids, sympathomimetics, and thyroid hormones may antagonize insulin action leading to hyperglycemia.
Certain diuretics (thiazides or loop) may impair glucose tolerance and diminish insulin efficacy.
ACE inhibitors and angiotensin II receptor blockers can enhance insulin sensitivity and increase hypoglycemia risk.
Monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs) may enhance or impair glucose control.
Fluoroquinolone antibiotics have been reported to cause hypoglycemia or hyperglycemia when administered with insulin.
Somatostatin analogs can inhibit insulin release and synergize with exogenous insulin effects.
Anabolic steroids and growth hormone may reduce insulin sensitivity requiring dose adjustment.
Drugs affecting gastrointestinal motility can alter absorption of nutrients and impact glucose control.
Medications suppressing the immune system, like tacrolimus or sirolimus, may affect glucose metabolism.
Certain herbal supplements and nutraceuticals may interact with insulin pharmacodynamics.
It is essential for patients to inform healthcare providers about all concomitant medications to avoid adverse interactions.

Preparations Of The Drug

U-100 regular insulin solution in vials (typically 10 mL multi-dose vials).
U-100 regular insulin cartridges compatible with reusable pen devices.
U-100 prefilled disposable insulin pens for ease of administration.
U-500 regular insulin concentrated solution available in vials and KwikPen prefilled pens for patients with high insulin requirements.
Intravenous insulin preparations used in hospital settings for emergent glycemic management.
Mixable formulations for combination with intermediate-acting insulin (e.g., NPH insulin) for premixed insulin products.
Preservative-containing formulations requiring reconstitution protocols and proper storage guidelines.
Ready-to-use solutions formulated for subcutaneous injection with sterile, pyrogen-free requirements.
Pre-filled pens equipped with dosing increments and memory features for patient convenience.
Specialized formulations for pediatric use with dosing flexibility.
Clinical-grade insulin for continuous subcutaneous insulin infusion (CSII) pumps in some cases, although regular insulin is less favored than rapid-acting analogs.
Vials and pens require refrigeration prior to use to maintain potency but may be kept at room temperature for limited periods while in use.
Packaging designed to prevent contamination and ensure correct dosing precision.
Clear, colorless solutions with particular lot-specific shelf life and expiration dates.
Preparation instructions emphasize not to freeze and discard if frozen or compromised.